Tekmira Expands Pipeline, Extends Cash Runway into 2013 | GenomeWeb

Tekmira Pharmaceuticals this week announced that it has expanded its pipeline with the addition of an siRNA-based drug candidate for alcohol dependence.

The company separately updated its cash guidance, stating that it has enough funds to carry it into the second half of 2013.

The new drug program focuses on aldehyde dehydrogenase 2, or ALDH2, which the company said is a “key enzyme" in ethanol metabolism.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.